Floatz logo

Aoc 1044

Duchenne Muscular Dystrophy

Avidity Biosciences, Inc.nucleic_acidPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

55 Active assets in the Duchenne Muscular Dystrophy cohort.

Asset / SponsorPhaseRating
Viltolarsen
NS Pharma, Inc.
Phase 4BBB
Golodirsen
Rare Disease Research, LLC
Phase 4BB
Delandistrogene Moxeparvovec
Sarepta Therapeutics, Inc.
Phase 3BB
Eteplirsen
Sarepta Therapeutics, Inc.
Phase 3BB
Glutamine
Assistance Publique - Hôpitaux de Paris
Phase 3BB

View all 49 →

Same molecule, other indications

Aoc 1044 is also rated in:

muscular dystrophyActive
B
Indicative · Phase 3
60 / 100
View asset →
muscular atrophyActive
B
Indicative · Phase 3
60 / 100
View asset →
muscle tissue disorderActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →